Search

Search Results

• THE USE OF BIOMIMETIC 2D AND 3D UROTHELIAL IN VITRO MODELS WITH MOLECULAR, MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTICS OF NORMAL AND CANCEROUS BLADDER TISSUE AS AN ALTERNATIVE METHOD IN PRECLINICAL STUDIES M.E. Kreft¹, L. Tratnjek¹, A. Janev¹, N. Resnik¹, U. Cerkvenik¹, U. D. Jerman¹, G. Markovič¹, T.Ž. Ramuta¹, T. Višnjar¹, Ž. Sardoč¹, A.Punčuh¹, S. Kralj², M. Čemažar³, P. Veranič¹ |¹Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; ²Department for Materials Synthesis, Jožef Stefan Institute, Ljubljana, Slovenia; ³Institute of Oncology Ljubljana, Ljubljana, Slovenia

  21-08-2025

  https://doi.org/10.4081/ejh.2025.4288

  186

• ANIMAL MODELS OF METASTATIC CANCER - ADVANCED IMAGE ANALYSIS FOR DISSECTION OF DRIVING SIGNALING PATHWAYS S. Alberti | University of Messina, Messina, Italy

  21-08-2025

  https://doi.org/10.4081/ejh.2025.4287

  160

• ANIMAL MODELS FOR LINEAGE TRACING IN (CELL) TRANSDIFFERENTIATION S. Cinti | Center for The Study of Obesity. Marche Polytechnic University, Ancona, Italy

  21-08-2025

  https://doi.org/10.4081/ejh.2025.4286

  143

• LEVERAGING ORGANOID TECHNOLOGIES TO CHARACTERIZE DYNAMIC TUMOR CELL STATES DRIVING TREATMENT RESISTANCE IN PANCREATIC CANCER A. Papargyriou^1-6, M. Najajreh^1-4, D.P. Cook⁷, C.H. Maurer^1,2, S. Bärthel⁸, P. Putze⁸, H.A. Messal⁹, S.K. Ravichandran^1-3, T. Richter¹⁰, M. Knolle¹¹, T. Metzler¹², A.R. Shastri^1,2,3, R. Öllinger¹³, J. Jasper^1,2,3, L. Schmidleitner^1,2,3, C.Schneeweis⁸, H. Ishikawa-Ankerhold¹⁴, T. Engleitner¹³, S. Dobiasch¹⁵, I. Heid, M.D. Luecken¹⁶, K. Steiger¹², G. Kaissis¹¹, J. Van Rheenen⁹, F.J. Theis¹⁰, D. Saur⁸, R. Rad¹³, M. Reichert^{1,2,3,4,5,17,18} | ¹Translational Pancreatic Cancer Research Center, Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Germany; ²Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich, Germany; ³Center for Functional Protein Assemblies, Technical University of Munich, Garching, Germany; ⁴Center for Organoid Systems (COS), Technical University of Munich, Garching, Germany; ⁵Bavarian Cancer Research Center (BZKF), Munich, Germany; ⁶Institute of Stem Cell Research, Helmholtz Center Munich, Neuherberg, Germany; ⁷University of Ottawa, Faculty of Medicine, Department of Cellular and Molecular Medicine, Ottawa, ON, Canada; ⁸Chair for Translational Cancer Research and Institute of Experimental Cancer Therapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Germany; ⁹Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. ¹⁰Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany; ¹¹Institute of Diagnostic and Interventional Radiology, Klinikum rechts der Isar München, Technical University of Munich, Germany; ¹²Comparative Experimental Pathology, Institut für Allgemeine Pathologie und Pathologische Anatomie, School of Medicine, Technical University of Munich, Germany; ¹³Institute of Molecular Oncology and Functional Genomics, School of Medicine, Technical University of Munich, Germany; ¹⁴Department of Medicine I, University Hospital of the LudwigMaximilians-University Munich, Germany; ¹⁵Department of Radiation Oncology, Technical University of Munich, Germany; ¹⁶Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Germany; Member of the German Center for Lung Research (DZL); ¹⁷German Cancer Consortium (DKTK), Munich, Germany; ¹⁸Munich Institute of Biomedical Engineering (MIBE), Technical University of Munich, Germany

  21-08-2025

  https://doi.org/10.4081/ejh.2025.4289

  243